Abstract: Treatment strategy and short-term outcome of peripheral arterial diseases with lifestream        ZOU Ling-wei, LIU Hao, CHEN Bin,et al. Department of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University；National Clinical Research Center for Interventional Medicine, Shanghai 200032, China 
Corresponding author：DONG Zhi-hui，E-mail:dzh926@126.com
ZOU Ling-wei and LIU Hao are the first authors who contributed equally to the article.
Abstract    Objective    To evaluate the treatment strategy and short-term outcome of Lifestream on peripheral arterial diseases. Methods    Clinical data of 37 patients who were treated with Lifestream in the Department of Vascular Surgery, Zhongshan Hospital, Fudan University from July 2020 to July 2021 were retrospectively analyzed. The survival, complications, and reintervention were recorded through postoperative follow-up. Results    The mean age of 37 patients were（65.3±10.2）years, including 34 males.48 Lifestreams were implanted with a mean stent diameter of（8.5±1.6）mm and length of（40.1±11.5）mm. There were 33 cases of iliac artery lesions in the affected limbs, 4 cases of carotid artery lesions, and 7 cases of subclavian artery lesions.The mean lesion length was（25.4±9.5）mm, and the rate of median stenosis was 85（80，90）Forty-eight at Lifestreams was implanted with a mean stent diameter of（8.5±1.6）mm and length of（ 40.1±11.5）mm, and the rate of technical success after Lifestream released at the intended site was 97.3%（36/37）. The median follow-up time was 8（6.5，12.0）months in 37 patients with no loss. The rates of postoperative all-cause mortality and target lesion revascularization（TLR）were both 0.No in-stent restenosis（ISR）was observed in the implanted Lifestream, and the stents were patency. The secondary intervention rate was 2.7%（1/37）and the freedom from major adverse event rate was 97.3%（36/37）. Significant improvement of the ankle-brachial index（ABI）in 33 affected limbs of 26 iliac artery patients compared to preoperative. Conclusion    Lifestream is safe, feasible, and effective in peripheral arterial disease.

Key words: peripheral arterial disease, endovascular treatment, covered stents

摘要： 目的    评价Lifestream支架在外周动脉疾病中的应用的安全性及短期疗效。方法    回顾性分析2020年7月至2021年7月在复旦大学附属中山医院收治并使用Lifestream支架进行治疗的37例病人资料。结果    37例（男性34例）病人平均（65.3±10.2）岁，髂动脉病变中患肢共33例，颈动脉病变4例，锁骨下动脉病变7例。病变平均长度为（25.4±9.5）mm，中位狭窄度为85%（80%，90%）。共植入48枚Lifestream支架，支架平均直径为（8.5±1.6）mm，长度为（40.1±11.5）mm。Lifestream支架在预定部位释放后技术成功率为97.3%（36/37）。37例病人中位随访时间为8.0（6.5，12.0）个月，无失访。术后全因死亡及靶血管血运重建（TLR）率均为0。植入的Lifestream支架均未出现支架内再狭窄（ISR），支架内血流畅通。二次干预率为2.7%（1/37），免于主要不良事件率为97.3%（36/37）。26例髂动脉病人的33条患肢的踝肱指数（ABI）较术前明显改善。结论    Lifestream支架在外周动脉疾病中的应用安全、可行、有效。

关键词: 外周动脉疾病, 腔内治疗, 覆膜支架